TetraLogic Pharmaceuticals Corp (TLOG)

TetraLogic Pharmaceuticals Corp. is a healthcare company listed on OTC Markets as common stock under the ticker TLOG. The company is a clinical-stage biopharmaceutical developer focused on small-molecule therapeutics for oncology and infectious diseases. Its pipeline includes two clinical-stage candidates: birinapant, a SMAC-mimetic designed to promote apoptosis in damaged cells, and SHAPE, a proprietary histone deacetylase inhibitor being developed as a topical treatment for early-stage cutaneous T-cell lymphoma. TetraLogic also has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to study SMAC-mimetics, including birinapant, in infectious disease applications. The company was incorporated in 2001, changed its name from Gentara Corporation in January 2006, and is headquartered in Malvern, Pennsylvania.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.